Why the study?
Fibrinolysis remains prevalent when timely primary PCI is unavailable, and adjunctive antithrombotic agents are of utmost importance to maximize its benefit.
Does fibrinolysis with optimal antithrombotic therapy achieve adequate angiographic outcomes in STEMI patients?
Does fibrinolysis with optimal antithrombotic therapy achieve adequate angiographic outcomes in STEMI patients?
Fibrinolysis with optimal antithrombotic therapy achieves favorable TIMI 3 flow rates in STEMI patients, supporting its utility in resource-limited settings where primary PCI is unavailable.
Suboptimal TIMI 3 flow despite optimal antithrombotics warrants caution with fibrinolysis in STEMI; leaves open need for better reperfusion strategies.
STEMI is a major public health problem requiring timely reperfusion. Fibrinolysis remains prevalent reperfusion strategy where timely primary percutaneous coronary intervention (PCI) cannot be performed. Adjunctive antithrombotic agents are of utmost importance for maximizing the benefit of fibrinolysis. This prospective study evaluates the angiographic outcomes in STEMI patients receiving fibrinolysis with optimal antithrombotic therapy and reported TIMI 3 flow rates of 33.8% and 41.5% for streptokinase and reteplase respectively, that were significantly higher than various prior studies. This data reiterates the utility of thrombolysis in resource limited settings.
No takes yet. Share an insight, caveat, or question.
Durdana et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: